DK0942740T3 - Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme - Google Patents

Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme

Info

Publication number
DK0942740T3
DK0942740T3 DK97953156T DK97953156T DK0942740T3 DK 0942740 T3 DK0942740 T3 DK 0942740T3 DK 97953156 T DK97953156 T DK 97953156T DK 97953156 T DK97953156 T DK 97953156T DK 0942740 T3 DK0942740 T3 DK 0942740T3
Authority
DK
Denmark
Prior art keywords
tfn
binding protein
treat
combination therapy
mediated diseases
Prior art date
Application number
DK97953156T
Other languages
English (en)
Inventor
Alison M Bendele
Regina M Sennello
Carl K Edwards
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0942740T3 publication Critical patent/DK0942740T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97953156T 1996-12-06 1997-12-08 Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme DK0942740T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3258796P 1996-12-06 1996-12-06
US3635597P 1997-01-23 1997-01-23
US3931597P 1997-02-07 1997-02-07
US5202397P 1997-07-09 1997-07-09
PCT/US1997/022733 WO1998024463A2 (en) 1996-12-06 1997-12-08 Combination therapy using a tnf binding protein for treating tnf-mediated diseases

Publications (1)

Publication Number Publication Date
DK0942740T3 true DK0942740T3 (da) 2003-12-15

Family

ID=27488013

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97953156T DK0942740T3 (da) 1996-12-06 1997-12-08 Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme

Country Status (12)

Country Link
US (4) US6306820B1 (da)
EP (1) EP0942740B1 (da)
JP (1) JP2001513754A (da)
AT (1) ATE247974T1 (da)
AU (1) AU5696198A (da)
CA (1) CA2273850A1 (da)
DE (1) DE69724451T2 (da)
DK (1) DK0942740T3 (da)
ES (1) ES2207759T3 (da)
HK (1) HK1022440A1 (da)
PT (1) PT942740E (da)
WO (1) WO1998024463A2 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
WO2000027421A2 (en) * 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
AU4363200A (en) * 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6537540B1 (en) * 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
CN101850120A (zh) * 1999-07-21 2010-10-06 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
ATE403437T1 (de) * 1999-12-14 2008-08-15 Genentech Inc Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
EP1294699B1 (en) 2000-05-12 2016-04-13 Genzyme Corporation Modulators of tnf- alpha signalling
MXPA02012879A (es) * 2000-06-20 2004-07-30 Herbst Arthur L Inhibidores de ciclooxigenasa-2 y la prevencion de los efectos secundarios de terapia por radiacion.
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
AU2001286701A1 (en) * 2000-08-31 2002-03-13 Genzyme Biosurgery Corporation Hyaluronan-based antiadhesion compositions, their preparation and use
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
DE10132308A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Kombinationspräparat zur Therapie von immunologischen Erkrankungen
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003282955A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
EP1567138B1 (en) * 2002-11-21 2011-01-05 Genzyme Corporation Use of a diamide derivative for inhibiting chronic transplant rejection
DK1562571T3 (da) * 2002-11-21 2011-12-05 Genzyme Corp Kombination af et diamidderivat og immunsuppressive midler til hæmning af transplantatafstødning
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
ES2375802T3 (es) 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation
KR20070100261A (ko) 2004-12-02 2007-10-10 캔-파이트 바이오파마 리미티드 염증 치료법
US8236306B2 (en) * 2004-12-18 2012-08-07 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
WO2006093784A2 (en) * 2005-02-25 2006-09-08 Mutual Pharmaceutical Company, Inc. Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
BR112012013330A2 (pt) * 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IN150740B (da) 1978-11-24 1982-12-04 Hoffmann La Roche
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
IL90339A (en) 1989-05-18 1996-10-16 Yeda Res & Dev Anti-cytotoxic protein and its purification
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
AU4660789A (en) 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
DE69017753T3 (de) 1989-05-18 2013-06-20 Yeda Research And Development Co., Ltd. Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
CA2485553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
DE69022559T2 (de) 1989-12-13 1996-05-02 Yeda Res & Dev Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
WO1992001002A1 (fr) 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE190629T1 (de) 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
EP0594772B1 (en) 1991-07-04 1996-08-28 Immunodex K/S Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Also Published As

Publication number Publication date
EP0942740A2 (en) 1999-09-22
ATE247974T1 (de) 2003-09-15
HK1022440A1 (en) 2000-08-11
CA2273850A1 (en) 1998-06-11
EP0942740B1 (en) 2003-08-27
WO1998024463A2 (en) 1998-06-11
DE69724451D1 (de) 2003-10-02
JP2001513754A (ja) 2001-09-04
US20020119924A1 (en) 2002-08-29
US20040047863A1 (en) 2004-03-11
PT942740E (pt) 2004-01-30
DE69724451T2 (de) 2004-03-18
US20040048799A1 (en) 2004-03-11
AU5696198A (en) 1998-06-29
US6306820B1 (en) 2001-10-23
ES2207759T3 (es) 2004-06-01
WO1998024463A3 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
MXPA05012011A (es) Uso terapeutico de anticuerpos anti-cs1.
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
NO983999D0 (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
DK1073456T3 (da) Anvendelse af osteoprotegerin til forebyggelse og behandling af kardiovaskulære sygdomme
DK1003494T3 (da) (d)-metadon, et ikke-opioidt analgetikum
SE9603725D0 (sv) New teatment
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69837322D1 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
CO4820397A1 (es) TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний